Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 20/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.69 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19641090 | 1.00 | PTPN11 (0.71) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL29910358 | 0.92 | PTPN11 (0.70) | PTPN11KCNH2 | |
| SCHEMBL19651404 | 0.92 | PTPN11 (0.60) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL19651465 | 0.92 | PTPN11 (0.70) | PTPN11KCNH2 | |
| SCHEMBL19641293 | 0.92 | PTPN11 (0.71) | PTPN11KCNH2 | |
| SCHEMBL19641121 | 0.92 | PTPN11 (0.71) | PTPN11KCNH2 | |
| SCHEMBL29910403 | 0.92 | PTPN11 (0.71) | PTPN11KCNH2 | |
| SCHEMBL20007948 | 0.91 | PTPN11 (0.61) | PTPN11KCNH2 | |
| SCHEMBL19656641 | 0.91 | PTPN11 (0.59) | PTPN11KCNH2 | |
| SCHEMBL26170397 | 0.91 | PTPN11 (0.59) | PTPN11KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840536-B2 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230109858-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-04-13 | — | — | US | disclosed |
| US-11466017-B2 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11466017-B2 | Heterocyclic inhibitors of PTPN11 | PTPRJ, PTPN11, PTPRCAP | PTPN11 2/4885KCNH2 4300/4885MAPK3 206/4885 |
| US-20230109858-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | PTPRJ, PTPN11, PTPRCAP | PTPN11 2/4885KCNH2 4300/4885MAPK3 206/4885 |
| US-11840536-B2 | Heterocyclic inhibitors of PTPN11 | PTPRJ, PTPN11, PTPRCAP | PTPN11 2/4885KCNH2 4300/4885MAPK3 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.